Wedbush Weighs in on iTeos Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:ITOS)

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Equities researchers at Wedbush lifted their FY2027 earnings per share estimates for shares of iTeos Therapeutics in a report issued on Sunday, September 15th. Wedbush analyst D. Nierengarten now expects that the company will earn ($6.51) per share for the year, up from their prior estimate of ($6.55). Wedbush has a “Outperform” rating and a $21.00 price target on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($4.21) per share. Wedbush also issued estimates for iTeos Therapeutics’ FY2028 earnings at ($2.70) EPS.

ITOS has been the topic of several other research reports. JPMorgan Chase & Co. cut their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research note on Monday. Finally, Wells Fargo & Company began coverage on iTeos Therapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price on the stock.

iTeos Therapeutics Trading Down 4.3 %

NASDAQ ITOS opened at $11.59 on Wednesday. The stock’s 50 day moving average is $16.12 and its 200 day moving average is $14.63. iTeos Therapeutics has a 12 month low of $8.20 and a 12 month high of $18.75. The stock has a market cap of $418.67 million, a PE ratio of -3.07 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.86. The business had revenue of $35.00 million for the quarter, compared to the consensus estimate of $4.20 million.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ITOS. China Universal Asset Management Co. Ltd. lifted its stake in shares of iTeos Therapeutics by 66.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock worth $94,000 after purchasing an additional 2,737 shares during the period. Quest Partners LLC acquired a new position in iTeos Therapeutics in the fourth quarter worth about $90,000. The Manufacturers Life Insurance Company grew its stake in iTeos Therapeutics by 6.6% in the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after purchasing an additional 690 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in iTeos Therapeutics by 35.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock worth $178,000 after acquiring an additional 3,172 shares during the last quarter. Finally, Aristides Capital LLC bought a new stake in shares of iTeos Therapeutics during the fourth quarter valued at approximately $157,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.